Key Drivers
- High liquidity
- Zero revenue
- Negative cashflow
AIAI Summary
CMPX is now an event‑driven, high‑upside/high‑downside trade centered on the April 2026 COMPANION‑002 PFS/OS readout — successful data could meaningfully revalue commercialization prospects, while negative or equivocal results would likely compress the stock sharply. Position sizing should therefore be small/speculative or wait‑and‑watch (buy post‑positive readout or near technical support with tight stops), as a strong balance sheet cushions near‑term dilution but does not eliminate clinical binary risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High liquidity
- •Zero revenue
- •Negative cashflow
CMPX combines strong liquidity and very low leverage with zero revenue, large operating losses and negative cash flow driven by R&D and investments, providing runway but high execution and commercialization risk.
Price Behavior
Key Price Behavior Insights:
- •Short-term downtrend
- •Support cluster
- •Elevated volatility
The stock is in a short-term downtrend—trading at $5.15 (~7.5% below its last month mean) with lower highs/lows since 2026-02-20, near-term support $5.15–$5.20, resistance $5.6–$5.7 (stronger $6.0–$6.4), and meaningful volatility (~$5.19–$6.17, ~18%) increasing short-term risk.
Price ranged from ~$5.19 to $6.17 (~18% span), indicating significant short-term volatility
Sentiment & News
Key News Insights:
- •Institutional stake
- •Trial milestone
- •Analyst bullishness
Compass Therapeutics gained momentum as a major institutional stake, a largely positive analyst "Moderate Buy" consensus, and trial progress—COMPANION‑002 hit its prespecified OS event threshold and CTX‑8371 cohorts expanded—positioning April 2026 for key readouts.
The combined institutional buy, favorable broker sentiment, and imminent PFS/OS analyses should heighten investor focus and make CMPX particularly sensitive to the April clinical readouts
Similar Companies in Healthcare
Other companies in the same sector with AI ratings